Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique

Histopathology

Volumn 50, Issue 4, 2007, Pages 472-483

  Mhawech Fauceglia, P ^a   Zhang, S ^a   Terracciano, L ^b   Sauter, G ^c   Chadhuri, A ^a   Herrmann, F R ^d   Penetrante, R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Immunoexpression; Prostatic adenocarcinoma; PSMA; TMA

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STAINING; TISSUE MICROARRAY; UROGENITAL TRACT TUMOR;

ADENOCARCINOMA; ANTIGENS, SURFACE; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; ORGAN SPECIFICITY; PROSTATE; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 33847319632     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02635.x     Document Type: Article

References (31)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization (WHO) classifications for tumours. Pathology and genetics of tumours of the urinary system and male genital organs, Chapter 3. Lyon: IARC Press 2004.
2. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: An autopsy study of 1589 patients. Hum. Pathol. 2000; 31; 578-583.
3. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum. Pathol. 2002; 33; 1136-1140.
4. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod. Pathol. 2000; 13; 1186-1191.
5. Goldstein NS. Immunophenotyping characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am. J. Clin. Pathol. 2002; 117; 471-477.
6. Chan TY, Mikolajczyk SD, Lecksell K et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003; 62; 177-181.
7. Epstein J. PSA and PAP as immunohistochemical markers in prostate cancer. Urol. Clin. North Am. 1993; 20; 757-770.
8. Ford TF, Butcher DN, Masters JR et al. Immunohistochemical localization of prostate-specific antigen: specificity and application to clinical practice. Br. J. Urol. 1985; 57; 50-55.
9. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am. J. Clin. Pathol. 2002; 117; 471-477.
10. Goldstein NS, Martinez A, Vicini F, Stromberg J. The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Am. J. Clin. Pathol. 1998; 110; 765-775.
11. Burger MJ, Tebay MA, Keith PA et al. Expression analysis of δ-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int. J. Cancer 2002; 100; 228-237.
12. Chang SS, Reuter VE, Heston WDW, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001; 57; 1179-1183.
13. Ross JS, Sheehan CE, Fisher HAG et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 2003; 9; 6357-6362.
14. Murphy GP, Elgamal A-AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998; 83; 2259-2269.
15. Marchal C, Redondo M, Padilla M et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostate intraepithelial neoplasia. Histol. Histopathol. 2004; 19; 715-718.
16. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999; 59; 3192-3198.
17. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997; 3; 81-85.
18. Chang SS, Reuter VE, Heston WD, Gaudin PB. Metastatic renal cell carcinoma neovasculature expressed prostate- specific membrane antigen. Urology 2001; 57; 801-805.
19. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 1999; 5; 2674-2681.
20. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular of tumor specimens. Nat. Med. 1998; 4; 844-847.
21. Lugli A, Forster Y, Hass P et al. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum. Pathol. 2003; 34; 994-1000.
22. Bubendorf L, Nocito A, Moch H et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J. Pathol. 2001; 195; 72-79.
23. Horoszewicz JS, Leong SS, Kawinski E et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983; 43; 1809-1818.
24. Pinto JT, Suffoletto BP, Berzin TM et al. Prostate-specific membrane antigen; a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 1996; 2; 1445-1451.
25. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl Acad. Sci. USA 1996; 93; 749-753.
26. Dumas F, Gala JL, Berteau P et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int. J. Cancer 1999; 80; 799-803.
27. Gala JL, Loric S, Guiot Y et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin. Cancer Res. 2000; 6; 4049-4054.
28. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res. 1994; 54; 1807-1811.
29. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 2004; 61; 1-11.
30. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol. 2003; 30; 667-676.
31. Chang SS, Heston WD. The clinical role of prostate-specific membrane antigen (PSMA). Urol. Oncol. 2002; 7; 7-12.